Examkin

Soru

Zorluk: OrtaHematology and Oncology

A 45-year-old female patient with newly diagnosed acute myeloid leukemia is currently undergoing induction chemotherapy in the oncology unit. On the tenth day of her treatment course, her body temperature spikes to 38.6°C (101.5°F). Vital signs show a blood pressure of 105/65 mm Hg, a heart rate of 110/min, and respirations of 18/min. She has a tunneled central venous catheter in place. Physical examination reveals no focal signs of infection; her lungs are clear to auscultation, and the catheter site exhibits no erythema or purulent discharge. Laboratory evaluation is notable for a leukocyte count of 400/mm³ with 10% neutrophils, resulting in an absolute neutrophil count of 40/mm³. A diagnosis of high-risk neutropenic fever is established.

Arrange the following clinical steps in the correct chronological sequence for the standard evaluation and management of this patient's condition.

  1. 1Obtain blood cultures from peripheral veins and all lumens of the central venous catheter.
  2. 2Initiate empiric intravenous broad-spectrum antibacterial therapy with antipseudomonal activity.
  3. 3Reassess the patient's clinical trajectory and review initial microbiological culture results.
  4. 4Add empiric systemic antifungal therapy.

Cevap

The correct sequence for managing high-risk neutropenic fever is: 1) Obtain blood cultures, 2) Initiate empiric antipseudomonal antibiotics, 3) Reassess at 48-72 hours, and 4) Add empiric antifungals if fever persists for 4-7 days.
The management of high-risk neutropenic fever relies on a strict, time-sensitive algorithm to minimize mortality. The sequence begins with identifying the potential pathogen by obtaining blood cultures from all lines to avoid altering the yield of the cultures. Immediately following culture collection, patients must receive broad-spectrum empiric antibiotics that cover Pseudomonas aeruginosa because bacterial infections are the most common and immediately life-threatening complications. At 48-72 hours, the initial regimen is formally reassessed based on the patient's clinical trajectory and preliminary culture results, allowing for de-escalation or targeted adjustments. Finally, if the patient remains persistently febrile after 4-7 days of appropriate antibacterial coverage without an identified source, the likelihood of an invasive fungal infection (such as candidiasis or aspergillosis) rises significantly, which warrants the addition of empiric systemic antifungal therapy.

Adım Adım Çözüm

1
Obtain blood cultures
Samples are secured for pathogen identification before drug interference.
Administering antibiotics before drawing cultures can sterilize the blood samples, preventing the identification of the organism and hindering targeted therapy.
2
Administer empiric antipseudomonal antibiotics
Broad-spectrum antibacterial coverage is immediately established.
Neutropenic patients lack the immune response to contain bacterial infections, making rapid initiation of therapy critical for survival.
3
Clinical and microbiological reassessment
Therapy is guided by 48-72 hour culture results and clinical status.
It typically takes 2 to 3 days for bacterial cultures to grow and for the patient to demonstrate a definitive clinical response to the initial empiric regimen.
4
Initiate empiric antifungal therapy
Coverage is expanded to treat potential invasive fungal pathogens.
Persistent fever in a profoundly neutropenic patient after 4 to 7 days of broad-spectrum antibacterial therapy is highly suggestive of an occult fungal infection.

Anahtar Kavram

The chronological management of high-risk neutropenic fever requires immediate culture acquisition, followed instantly by antipseudomonal antibacterial therapy, a formal reassessment at 48-72 hours, and the addition of antifungal therapy only if fevers persist beyond 4-7 days.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru